摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-phenylpropoxy)propan-1-ol

中文名称
——
中文别名
——
英文名称
3-(3-phenylpropoxy)propan-1-ol
英文别名
1-(3-phenyl-propyloxy)-propanol-(3);3-Hydroxy-1-(3-phenyl-propyloxy)-propan;(3-Hydroxy-propyl)-(3-phenyl-propyl)-aether
3-(3-phenylpropoxy)propan-1-ol化学式
CAS
——
化学式
C12H18O2
mdl
——
分子量
194.274
InChiKey
JMINNHUTENQXPU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    14
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-苯乙基-1,3-二恶烷1,1,3,3-四甲基二硅氧烷 、 palladium on carbon 、 camphor-10-sulfonic acid 作用下, 反应 24.0h, 以99%的产率得到3-(3-phenylpropoxy)propan-1-ol
    参考文献:
    名称:
    TMDS–Pd / C:一种将乙缩醛还原为醚的便捷系统
    摘要:
    描述了一种用于将缩醛还原为醚的简单实用的方法。它是基于在布朗斯台德酸作为助催化剂的情况下使用1,1,3,3-四甲基二硅氧烷(TMDS)-Pd / C体系。该反应在温和的条件下进行,并且以高收率获得醚。
    DOI:
    10.1016/j.tetlet.2011.01.038
点击查看最新优质反应信息

文献信息

  • [EN] CARBOSTYRIL COMPOUND<br/>[FR] DÉRIVÉ DE CARBOSTYRILE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2006035954A1
    公开(公告)日:2006-04-06
    The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
    本发明提供了一种由通式(1)表示的羧基吲哚化合物或其盐,其中A是直链键、较低的烷基烯基或较低的烷基亚烯基;X是氧原子或原子;R4和R5分别表示氢原子;羧基吲哚骨架的3和4位置之间的键是单键或双键;R1是氢原子,等等;R2是氢原子,等等;R3是氢原子,等等。本发明的羧基吲哚化合物或其盐诱导TFF的产生,因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和伤口等疾病。
  • Environmentally benign metal triflate-catalyzed reductive cleavage of the C–O bond of acetals to ethers
    作者:Yin-Jie Zhang、Wissam Dayoub、Guo-Rong Chen、Marc Lemaire
    DOI:10.1039/c1gc15636e
    日期:——
    A protocol is described for the reductive cleavage of the C–O bond of aromatic and aliphatic acetals to ethers catalyzed by Cu(OTf)2 or Bi(OTf)3 at room temperature in excellent yields, without affecting aromatic rings, nitro, nitrile, ester and hydroxyl groups. This protocol represents an improvement in terms of atom economy compared to the previous methods, by distinctly decreasing the amount of
    描述了还原性裂解芳香族和脂肪族C-O键的方案 缩醛 到 醚 由...催化 (OTf)2 或者 (OTf)3 在室温下以优异的收率,而不会影响芳环, 硝基的, 腈, 酯 和 羟 团体。与以前的方法相比,该协议通过显着减少还原剂的用量,代表了原子经济性方面的改进。1,1,3,3-四甲基二硅氧烷 (TMDS),并使用少量 催化剂。
  • Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor
    申请人:Duran Carlos Puig
    公开号:US20090042933A1
    公开(公告)日:2009-02-12
    A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R 1 is a group chosen from —CH 2 OH and —NHC(O)H; R 2 is a hydrogen atom or R 1 together with R 2 form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R 1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R 2 ; R 3 is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R 5 , —SO 2 —R 5 , —NH—CO—NH 2 , —CO—NH 2 , hydantoino, C 1-4 alkyl, C 1-4 alkoxy and —SO 2 NR 5 R 6 ; R 4 is chosen from a hydrogen atom, a halogen atom and a C 1-4 alkyl group; R 5 is chosen from a C 1-4 alkyl group and a C 3-8 cycloalkyl group; R 6 is independently chosen from a hydrogen atom and a C 1-4 alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.
    化合物的化学式(I)或其药学上可接受的盐、溶剂化合物或立体异构体,其中R1是从—CH2OH和—NHC(O)H中选择的基团;R2是氢原子或R1与R2一起形成—NH—C(O)—CH═CH—的基团,其中氮原子与持有R1的苯环中的碳原子结合,碳原子与持有R2的苯环中的碳原子结合;R3从氢原子、卤原子和从—SO—R5、—SO2—R5、—NH—CO—NH2、—CO—NH2、hydantoino、C1-4烷基、C1-4烷氧基和—SO2NR5R6中选择的基团;R4从氢原子、卤原子和C1-4烷基中选择;R5从C1-4烷基和C3-8环烷基中选择;R6独立选择从氢原子和C1-4烷基中选择;n、p和q独立选择0、1、2、3或4;m和s独立选择0、1、2或3;r为0、1或2,但至少有一个m和r不为0,n+m+p+q+r+s之和为7、8、9、10、11、12或13,且q+r+s之和为2、3、4、5或6。
  • Carbostyril compound
    申请人:Kuroda Takeshi
    公开号:US20070179173A1
    公开(公告)日:2007-08-02
    The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R 4 and R 5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R 1 is a hydrogen atom, etc; R 2 is a hydrogen atom, etc; and R 3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
    本发明提供了一种由通式(1)表示的碳基噻吩化合物或其盐,其中A是直接键,较低的烷基烷基或较低的烷基亚烷基;X是氧原子或原子;R4和R5分别表示氢原子;碳基噻吩骨架的3和4位之间的键是单键或双键;R1是氢原子等;R2是氢原子等;R3是氢原子等。本发明的碳基噻吩化合物或其盐能够诱导TFF的产生,因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和伤口等疾病。
  • Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor
    申请人:PUIG DURAN Carlos
    公开号:US20120101075A2
    公开(公告)日:2012-04-26
    The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    本公开涉及式(I)的4-(2-基-1-羟乙基)苯酚生物,以及包含它们的药物组合物,以及它们作为BETA2肾上腺素能受体激动剂在治疗中的使用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫